RIKODEINE® Cough Liquid (Dihydrocodeine Tartrate)

RIKODEINE® Cough Liquid (Dihydrocodeine Tartrate)

1. Product Overview

Rikodeine is a pharmacist-only oral liquid containing dihydrocodeine, a semi-synthetic opioid analgesic and potent cough suppressant. Marketed primarily in Australia and New Zealand by iMedicare (formerly Aspen Pharmacare/Mundipharma), it is positioned as a second-line treatment for stubborn, irritating dry coughs that have not responded to simpler treatments (e.g., pholcodine or dextromethorphan). The product is presented as a dark red/cherry-flavored syrup in amber glass bottles (100 mL and 200 mL sizes) with child-resistant screw caps.

---

2. Chemical Composition & Formulation

Note: This formulation is alcohol-free (ethanol-free), reducing interaction risks with other CNS depressants compared to older codeine syrups.

---

3. Therapeutic Indication

Primary Use: Symptomatic relief of severe, dry (non-productive) cough unresponsive to non-opioid antitussives.

Clinical Context:

• Suitable for adults and adolescents over 12 years (age restrictions vary by jurisdiction—often 18+ due to opioid content).
• Specifically indicated when cough suppression is medically desirable (e.g., post-operative coughing causing pain, cough-induced insomnia, or dry hacking cough from viral URTIs without sputum production).
• Not indicated for: Asthmatic coughs, productive/wet coughs requiring expectoration, or chronic obstructive pulmonary disease (COPD) without specialist supervision.

---

4. Pharmacology & Mechanism of Action

Class: Semi-synthetic opiate; derivative of codeine (~1.4–2.0x potency of codeine, roughly equiparent to hydrocodone).

Mechanism:

• Acts centrally as an agonist at μ-opioid receptors in the medullary cough center (area postrema/nucleus tractus solitarius), raising the threshold for cough reflex initiation.
• Also possesses mild-to-moderate analgesic properties via supraspinal spinal cord modulation, though this is secondary to its antitussive effect at therapeutic doses.
• Antitussive onset: 20–30 minutes after oral administration.
• Duration of action: 4–6 hours (half-life ~3.5–5 hours).

---

5. Directions for Use (Standard Protocol)

Adults & Children ≥12 years (per local guidelines):

• Dosage: 5 mL (10 mg) every 4–6 hours as needed.
• Maximum Daily Dose: 30 mg (15 mL) in 24 hours (strict limit to prevent toxicity).
• Duration of Use: Maximum 5 consecutive days unless directed by a doctor. Longer use increases risk of tolerance, dependence, and rebound cough hypersensitivity (opioid-induced hyperalgesia).

Special Populations:

• Elderly/Hepatic Impairment: Reduce dose by 25–50%; monitor for excessive sedation/respiratory depression.
• Renal Impairment: Avoid accumulation; use lower doses or extended intervals.
• Children <12 years: Contraindicated (risk of life-threatening respiratory depression).

Administration:
Oral use only. Measure with provided dosing cup/syringe. Do not mix with alcoholic beverages.

---

6. Critical Safety Information & Warnings

⚠️ High-Alert Classifications:

• S3 (Australia): “Pharmacist Only Medicine” – Must be sold behind-the-counter with mandatory pharmacist consultation regarding risk minimization.
• Controlled Substance Status: Dihydrocodeine is scheduled under drug control laws in most countries due to abuse potential (Schedule II/V depending on jurisdiction).

Contraindications (Do Not Use If):

1. Acute respiratory depression, acute severe asthma, or hypercapnia (CO₂ retention).
2. Known hypersensitivity to opioids, dihydrocodeine, or any excipient.
3. Concurrent use of monoamine oxidase inhibitors (MAOIs) (within last 14 days) – risk of serotonin syndrome/hypertensive crisis.
4. Paralytic ileus or abdominal surgical conditions where peristalsis is critical.
5. Pregnancy (Category C) – crosses placenta; neonatal respiratory depression possible.
6. Breastfeeding – excreted in milk; can cause infant sedation/apnea.

Major Drug Interactions:

---

7. Adverse Effect Profile

Common (>5%):

• Constipation (opioid bowel dysfunction) – often requiring prophylactic laxatives.
• Nausea/vomiting, epigastric discomfort.
• Sedation/drowsiness, dizziness, lightheadedness.
• Dry mouth, facial flushing.

Serious/Rare (<1% – Require Immediate Medical Attention):

• Respiratory depression (bradypnea <10 breaths/min, cyanosis).
• Hypotension, syncope.
• Physical dependence, psychological addiction (craving, drug-seeking behavior) with prolonged use.
• Seizures (particularly if history of epilepsy or head trauma).
• Urinary retention (especially in prostatic hypertrophy).

Long-Term Risks:
Rebound tachyphylaxis (tolerance) may occur within days; abrupt discontinuation after >1 week use can precipitate withdrawal (agitation, rhinorrhea, myalgia, piloerection).

---

8. Overdose Management

Toxicity Signs: Pinpoint pupils (miosis), profound somnolence/coma, skeletal muscle flaccidity, bradycardia, hypotension, respiratory arrest (death).

Emergency Treatment:

1. Maintain airway (intubation/ventilation if needed); administer 100% oxygen.
2. Naloxone (Narcan) IV titrated every 2–3 minutes to reverse respiratory depression (may need repeat dosing due to dihydrocodeine’s longer half-life than naloxone).
3. Gastric lavage if presentation <1 hour post-ingestion; activated charcoal (50g adult dose).
4. Supportive care (IV fluids, vasopressors for hypotension).

---

9. Patient Counseling Points (Critical for Pharmacist)

Before dispensing, verify:

• ✅ Patient age (>12 years ideally >18 years locally).
• ✅ No history of substance use disorder (opioid dependence risk).
• ✅ No concurrent driving/operating heavy machinery requirements (impairment occurs).
• ✅ Understanding that <5 days use only to prevent habituation.
• ✅ Not mixing with alcohol (“one drink equals double effect”).
• ✅ Laxative prophylaxis advised if >3-day course.
• ✅ Return unused medication to pharmacy for disposal (do not flush down toilet—environmental hazard).

---

10. Storage & Stability

• Temperature: Store below 25°C (77°F); do not freeze. Protect from light (amber bottle essential).
• Shelf Life: Typically 24 months from manufacture; discard 6 months after opening (oral liquids support microbial growth despite preservatives).
• Container: Keep tightly closed in original container (child-resistant cap required by law).

---

11. Regulatory & Legal Summary

---

Conclusion & Risk Stratification

Rikodeine represents a high-potency, controlled-access therapeutic option appropriate only for carefully selected patients with debilitating dry cough who fail first-line therapies. Its utility is strictly bounded by the narrow therapeutic window between effective cough suppression and opioid-induced adverse events. It is not a benign remedy; possession carries responsibility for safe storage, adherence to temporal limits, and awareness of central nervous system depression risks.

Disclaimer: This information is for educational purposes and does not constitute medical advice. Always read Consumer Medicines Information (CMI) leaflets and consult a healthcare professional before initiating treatment.